Ofloxacin 0.3% ophthalmic solution is used in veterinary patients for treatment of bacterial conjunctivitis or keratitis caused by susceptible strains of Staphylococcus spp, Streptococcus spp, Pseudomonas aeruginosa, Chlamydophila spp, and Haemophilus spp. Made by Apexa.
Ofloxacin 0.3% Ophthalmic Solution is a drug labeled for use in humans that is used extra label in the treatment of veterinary patients with bacterial conjunctivitis and keratitis.
Contains: Active: ofloxacin 0.3% (3 mg/mL);
Preservative: benzalkonium chloride (0.005%);
Inactives: sodium chloride and water for injection. May also contain hydrochloric acid and/or sodium hydroxide to adjust pH.
Ofloxacin Ophthalmic Solution USP, 0.3% is unbuffered and formulated with a pH of 6.4 (range - 6.0 to 6.8). It has an osmolality of 300 mOsm/kg. Ofloxacin is a fluorinated 4-quinolone which differs from other fluorinated 4-quinolones in that there is a six member (pyridobenzoxazine) ring from positions 1 to 8 of the basic ring structure.
Ofloxacin 0.3% Ophthalmic Solution is available in a 5-mL and 10-mL ophthalmic dropper bottles.
Use as directed by your veterinarian.
COMMONLY RECOMMENDED DOSAGES:
Conjunctivitis (extra-label): 1 drop in the affected eye(s) every 2-8 hours
Keratitis (extra-label): 1 drop in the affected eye(s) or 0.1 mL in a subpalpebral lavage (SPL) catheter every 2-8 hours. May precipitate when mixed with other ophthalmic medications, therefore it is important to flush subpalpebral lavage catheter well with air between medications.
- Used 3-12 times daily.
- Crystals may appear on the ocular surface after initiation of treatment.
- Wait 5 minutes after applying this medication before applying any other medications to the eye.
- Store in the refrigerator or at controlled room temperature away from moisture and sunlight; do not freeze.
- Do not use if the color changes, it becomes cloudy, or if particles are seen in solutions.
Contraindications / Precautions / Warnings
Ofloxacin is contraindicated in patients with a history of hypersensitivity to ofloxacin, to other fluoroquinolones, or to any of the components of this medication. For topical ophthalmic use only; not for injection subconjunctivally or into the anterior chamber of the eye. Fluoroquinolone-induced retinal toxicity in domestic cats has not been demonstrated with this product.
Adverse effects reported in humans or animals include blurred vision, tearing, eye pain, redness, itching, and a bad taste in the mouth. Crystalline drug precipitates may be noted in the superficial portion of corneal defects during use. Alterations in ocular surface microflora, with increased population of resistant organisms, has been documented in dogs during 6 weeks of topical ofloxacin therapy following cataract surgery.